AnaptysBio, Inc.
ANAB
$59.43
-$0.56-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -26.79M | -13.23M | -84.63M | -132.59M | -140.62M |
| Total Depreciation and Amortization | 2.43M | 2.42M | 2.42M | 2.40M | 2.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 120.74M | 111.23M | 106.64M | 97.13M | 85.91M |
| Change in Net Operating Assets | -91.90M | -80.73M | -169.40M | -94.65M | -56.46M |
| Cash from Operations | 4.48M | 19.70M | -144.97M | -127.71M | -108.78M |
| Capital Expenditure | -69.00K | -87.00K | -349.00K | -372.00K | -366.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 248.24M | 228.12M | 125.49M | 80.85M | 42.00M |
| Cash from Investing | 248.17M | 228.03M | 125.14M | 80.47M | 41.63M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27.99M | 14.26M | 2.60M | 100.77M | 100.32M |
| Repurchase of Common Stock | -64.20M | -68.63M | -65.70M | -55.98M | -4.88M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -66.60M | -78.25M | 1.18M | -25.08M | 16.66M |
| Cash from Financing | -102.81M | -132.61M | -61.91M | 19.71M | 112.10M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 149.83M | 115.12M | -81.75M | -27.52M | 44.94M |